Dr Reddy’s in focus: The pharma giant is expected to report a muted performance for Q4FY26, with consensus estimates pointing to a sharp year-on-year decline in earnings due to pressure in its key U.S. business and the absence of gRevlimid contribution following patent expiry. While domestic growth and traction in select international markets may provide some support, overall profitability is likely to remain under strain, with margins compressing significantly amid pricing pressures and portfolio adjustments.
Other Expectations Q4FY26 Dr Reddy’s
Dr Reddy Q3FY26 Result
The pharma company’s net profit for the quarter fell 14 per cent year-on-year and 16 per cent quarter-on-quarter to Rs 1,210 crore, with a PAT margin of 13.9 per cent.
The large-cap pharma company’s revenue stood at Rs 8,727 crore, a 4.4 per cent year-on-year increase, while declining 0.9 per cent sequentially. Growth during the quarter was driven by the core business, excluding the impact of specific products.
The company’s EBITDA came in at Rs 2,049 crore, with an EBITDA margin of 23.5 per cent. EBITDA declined 11 per cent year-on-year and 13 per cent quarter-on-quarter, reflecting pressure from product-related factors
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
